No verified content for a specific article from the New England Journal of Medicine (Volume 394, Issue 8, Pages 825-826) on engasertib in hereditary hemorrhagic telangiectasia was found in the search results provided. The search contains only general information about hereditary hemorrhagic telangiectasia (HHT), its symptoms such as recurrent nosebleeds, and treatment with drugs such as bevacizumab or thalidomide[1][2][3]. Without the direct text of the article, I cannot create a summary based only on verified facts from it. I recommend providing the full text of the article for an accurate summary.